Keep Your Eyes on These Stocks: FRX, NAV, DMND, CNC, AMPE, RHHBY – ValueWalk Premium

Keep Your Eyes on These Stocks: FRX, NAV, DMND, CNC, AMPE, RHHBY

Keep Your Eyes on These Stocks: FRX, NAV, DMND, CNC, AMPE, RHHBY

The following stocks have news that should keep them trading actively on Monday.

Forest Laboratories (NYSE:FRX)

The company lowered its fiscal year 2013 earnings guidance after announcing that its March patent exclusivity expiration on Lexapro, its treatment for depression, affected the company more than expected. The first prices from approved distributor Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) was lower than the company expected, cutting into royalty income.

Shares of Forest Labs are down 3.59 percent to $34.41.

Navistar International (NYSE:NAV)

Activist investor Carl Icahn increased his stake in the company, suggesting a fresh interest in the company. It has been struggling and saw two consecutive quarters of losses with its restructured management.

Shares of Navistar are up 2.61 percent to $29.10.

Diamond Foods Inc. (NYSE:DMND)

The company said it wouldn’t meet Monday’s Nasdaq deadline for filing quarterly reports. As a result, the company will likely get a delisting warning. It could appeal this to delay a potential listing pull from the exchange.

Diamond Foods will also ask for an extension for the date of its annual meeting; this isn’t likely to happen prior to July 31.

Shares of Diamond Foods are down 9.23 percent to $18.30.

Centene Corp. (NYSE:CNC) 

The company cut its full-year earnings guidance after seeing higher-than-expected medical costs in Kentucky and Texas as well as from its Celtic business. It is also prepping for a possible writedown.

Shares of Centene are down 23.06 percent to $27.29.

Ampio Pharmaceuticals Inc. (NASDAQ:AMPE)

The company announced good trial results from its retina swelling treatment due to diabetes.

Shares of Ampio Pharmaceuticals are up 6.64 percent to $3.41.

Roche Holding Ltd (RHHBY)

The company took Illumina (ILMN) off its M&A to-buy list and will now instead focus on the evolving DNA sequencing field through  internal projects and partnerships. Roche CEO Severin Schwan doesn’t plan to lose sleep over the unsuccessful bid.


Saved Articles

The top investors are reading ValuewalkPremium.

Click here to learn why